Reflection of Adjuvant Treatment Approaches for Early Stage Testis Tumors in Our Clinic
Journal Title: Üroonkoloji Bülteni - Year 2018, Vol 17, Issue 2
Abstract
Objective: Treatment modalities applied after orchiectomy in early-stage germ cell tumors (GCTs) include significant changes in each new study. In this study we reevaluated the treatment approaches used in our hospital between 2010-2014 according to current guidelines. Materials and Methods: We retrospectively evaluated the oncologic treatments and follow-up data of 32 patients who underwent radical orchiectomy between January 2010 and December 2014 due to testicular tumor and were diagnosed with early stage GCT in the Urology Clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital of University of Health Sciences. Results: Of 19 patients diagnosed with stage 1 seminomas, 3 patients in the low risk group were followed. Of 4 patients who received single-dose carboplatin therapy, 2 were at low risk and 2 were at high risk. Therefore, 2 patients at low-risk had overtreatment. Twelve patients were treated with radiotherapy (RT) that was no longer recommended in guidelines after 2014. Two patients in the low risk group of stage 1 non-seminoma were followed. One of them had recurrence at 12 months, and received 3 cycles of bleomycin + etoposide + cisplatin (BEP) according to current guidelines. Four patients with stage 1 non-seminoma underwent 2 cycles of BEP because they were considered at high risk. These patients are now recommended to receive 1 cycle BEP according to the current guidelines. While 4 patients with stage 1 mixed GCT were followed because of low risk, one patient was administered 2 cycle of BEP based on the old guidelines, at that time because of high risk. In the seminoma group that was administered RT, acute myeloblastic leukemia and oligospermia toxicity were detected, but these were not observed in the carboplatin group. One of high-risk non-seminoma patients who received 2 doses of BEP developed Myelodysplastic syndrome. Conclusion: Early-stage GCTs have high cancer-specific and overall survival rates with appropriate treatment approaches. Although there are still controversial issues regarding their management, treatment approaches are changing with each study. Therefore, it is crucial to remain informed about current international guidelines and new scientific studies.
Authors and Affiliations
İsmail Selvi, Erdem Öztürk, Taha Numan Yıkılmaz, Nurullah Hamidi, Halil Başar
Keywords
Related Articles
- EP ID EP379741
- DOI 10.4274/uob.973
- Views 104
- Downloads 0
Should We Perform Thoracic Imaging for Every Patient with a Renal Mass?
Objective: Current guidelines for the management of renal mass recommend thoracic imaging for potential metastatic nodules. Small size of the renal mass can be associated with low metastatic potential, which might questi...
Gleason Score Correlation Between Prostate Biopsy and Radical Prostatectomy Specimens
Objective: Prostate cancer is the most common malignancy in men and the second cause of cancer-related mortality. Prostate biopsy and the Gleason score guide treatment decisions in prostate cancer. Several studies have i...
Does the Future of Prostate Cancer Treatment Lie with Apoptotic Inducers?
Despite present-day clinical achievements which can extend the overall survival period, prostate cancer (PCa) related mortality remains a major problem. Resistance against apoptosis which consequently leads to disease pr...
Predictive Value of Hormonal Evaluation Before Prostate Needle Biopsy on Prostate Cancer T Stage and Prognosis
Objective: In this study we evaluated the hormone data before prostate needle biopsy (PNB) in patients who underwent retropubic radical prostatectomy (RRP) due to prostate adenocarcinoma (PCa). Correlations between the p...
Determination of Six Transmembrane Protein of Prostate 2 Gene Expression and Intracellular Localization in Prostate Cancer
Objective In this study, we aimed to determine the relationship between the RNA and protein expression profile of six transmembrane protein of prostate 2 (STAMP2) gene and androgen and the intracellular localization of...